OBSIDIAN THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN THE REGISTRATION-ENABLING COHORT OF PHASE 1/2 AGNI-01 STUDY EVALUATING AMSOKI-CEL (OBX-115) IN ADVANCED MELANOMA

Reuters · 1d ago

Please log in to view news